Key facts
- Notable investors include Roche Venture Fund.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Receptive Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Receptive Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Receptive Bio
Developer of receptor-mediated shuttles intended to unlock therapeutic delivery to the brain and beyond. The company is currently operating in Stealth mode.
- Sector
- Business Products and Services (B2B)
- HQ
- Basel, Switzerland
- Website
- receptivebio.com/
- Ownership
- Privately Held (backing)
Receptive Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Receptive Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Receptive Bio in its N-PORT filings yet. We sweep new filings monthly.